Xender to distribute 10,000 CyberCare systems
Xender to distribute 10,000 CyberCare systemsXender Corporation, a Taiwanese electronic instruments manufacturer, has signed a licensing agreement with CyberCare, a technology-based health management company, to manufacture, sell, and distribute
Xender to distribute 10,000 CyberCare systems
Xender Corporation, a Taiwanese electronic instruments manufacturer, has signed a licensing agreement with CyberCare, a technology-based health management company, to manufacture, sell, and distribute 10,000 CyberCare Electronic HouseCall systems over the next three years. Under terms of the deal, Xender will pay CyberCare a $500 per unit royalty fee to install, operate, and maintain the communications network in Taiwan and will receive a recurring network fee of $200 per month per installed unit.
Xender claims to have established relationships with more than 300 medical facilities in Taiwan and expects these customers to purchase the Electronic HouseCall system to enhance care for their chronically ill patients. The Electronic HouseCall is an Internet-based system for remote monitoring of patients.
- Search Again
- Return To HNN Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
